Markets:

Overview

News

Currencies

International

Treasuries

ResMed Inc. Common Stock (NY:RMD)

222.88 -0.26 (-0.12%)

Streaming Delayed Price Updated: 9:40 AM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Peering Into ResMed's Recent Short Interest ↗

July 08, 2022

ResMed's (NYSE:RMD) short percent of float has risen 14.44% since its last report. The company recently reported that it has 1.50 million shares sold short, which is 1.03% of all...

Via Benzinga

7 Growth Stocks to Buy in July 2022 ↗

July 04, 2022

The severe macroeconomic climate has led investors toward defensive plays, creating buy opportunities in the following growth stocks.

Via InvestorPlace

Analyzing ResMed's Short Interest ↗

June 22, 2022

ResMed's (NYSE:RMD) short percent of float has risen 5.62% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 0.94% of all...

Via Benzinga

Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years ↗

June 15, 2022

ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 9.9% on an annualized basis producing an average annual return of 16.19%. Currently, ResMed has a market capitalization of $29.81...

Via Benzinga

ResMed Strengthens Its Out-Of-Hospital Software Solutions Position With Latest Acquisition - Read How ↗

June 14, 2022

Via Benzinga

Analyst Ratings for ResMed ↗

June 06, 2022

Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter:

Via Benzinga

ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract ↗

April 29, 2022

Via Benzinga

What 5 Analyst Ratings Have To Say About ResMed ↗

April 06, 2022

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:

Via Benzinga

Expert Ratings For ResMed ↗

January 31, 2022

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

June 06, 2022

Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.

Via Benzinga

A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street ↗

June 06, 2022

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Nasdaq tumbled over 300 points in the previous session despite better-than-expected jobs report for May.

Via Benzinga

If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today ↗

June 02, 2022

ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of...

Via Benzinga

ResMed Earnings Perspective: Return On Invested Capital ↗

May 03, 2022

Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters.

Via Benzinga

What 3 Analyst Ratings Have To Say About ResMed ↗

April 29, 2022

Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's...

Via Benzinga

Recap: ResMed Q2 Earnings ↗

January 27, 2022

ResMed (NYSE:RMD) reported its Q2 earnings results on Thursday, January 27, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ResMed missed...

Via Benzinga

Earnings Scheduled For January 27, 2022 ↗

January 27, 2022

Companies Reporting Before The Bell • SAP (NYSE:SAP) is estimated to report quarterly earnings at $1.87 per share on revenue of $9.10 billion. •...

Via Benzinga

Sleep Apnea Device Maker Resmed Sees Improved Relative Strength ↗

January 14, 2022

Resmed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

Earnings Outlook For ResMed ↗

April 27, 2022

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗

April 06, 2022

Upgrades

Via Benzinga

Ten Healthcare Companies With High Payout Ratio ↗

March 25, 2022

The healthcare industry is among the biggest U.S. market segments in terms of market capitalization, but when it comes to dividend payouts, they rank very low.

Via Talk Markets

3 Top S&P 500 Stock Market Gainers Today: Energy Dominates As Adobe Dives ↗

March 23, 2022

Energy and commodity plays were top performers Wednesday.

Via Investor's Business Daily

Markets Fall Amid Rising Oil Prices ↗

March 23, 2022

U.S. indices finished lower Wednesday as investors continue to weigh the Federal Reserve tapering outlook, inflation concerns and the Russia-Ukraine war. Oil prices have also...

Via Benzinga

3 Beaten-Down Growth Stocks With More Than 50% Upside Potential ↗

February 25, 2022

The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions.

Via InvestorPlace

Ominous Death Cross Forms On ResMed's Chart ↗

February 02, 2022

If history is any guide, there may be trouble ahead for shares of ResMed (NYSE:RMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

ResMed's Return on Invested Capital Overview ↗

January 28, 2022

According to Benzinga Pro, during Q2, ResMed (NYSE:RMD) earned $201.75 million, a 0.91% increase from the preceding quarter. ResMed's sales decreased to $894.87 million, a 1.01%...

Via Benzinga

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron ↗

January 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall ↗

January 28, 2022

ResMed Inc (NYSE: RMD) revealed a 13% Y/Y jump in Q2 FY22 revenue to $894.9 million, missing the consensus of $935.25 million. The growth was below analyst expectations...

Via Benzinga

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study ↗

January 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview: ResMed ↗

January 26, 2022

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-01-27. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.